<\/p>\n
According to the Schizophrenia<\/a> and Related Disorders Alliance of America, approximately 3.5 million people in the United States are diagnosed with schizophrenia (n.d.), and it is one of the leading causes of disability. In practice, patients may present with delusions, hallucinations, disorganized thinking, disorganized or abnormal motor behavior, as well as other negative symptoms that can be disabling for these individuals. Not only are these symptoms one of the most challenging symptom clusters you will encounter, many are associated with other disorders, such as depression, bipolar disorder, and disorders on the schizophrenia spectrum. As a psychiatric nurse practitioner, you must understand the underlying neurobiology of these symptoms to select appropriate therapies and improve outcomes for patients.<\/p>\n This week, as you examine antipsychotic therapies, you explore the assessment and treatment of patients with psychosis and schizophrenia. You also consider ethical and legal implications of these therapies.<\/p>\n Schizophrenia and Related Disorders Alliance of America. (n.d.). About\u00a0 schizophrenia<\/em>.https:\/\/sardaa.org\/resources\/about-schizophrenia\/#:~:text=Quick%20Facts%20About%20Schizophrenia.%20Schizophrenia%20can%20be%20found,is%20one%20of%20the%20leading%20causes%20of%20disability<\/a><\/sub><\/p>\n <\/p>\n Required Readings (click to expand\/reduce) <\/a><\/u><\/strong><\/p>\n <\/p>\n Freudenreich, O., Goff, D. C., & Henderson, D. C. (2016). Antipsychotic drugs. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), Massachusetts General Hospital psychopharmacology and neurotherapeutics<\/em>\u00a0(pp. 72\u201385). Elsevier.<\/p>\n American Psychiatric Association. (2019). Practice guideline for the treatment of patients with schizophrenia<\/em>. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Practice\/Clinical%20Practice%20Guidelines\/APA-Draft-Schizophrenia-Treatment-Guideline.pdf<\/a><\/u><\/p>\n Clozapine REMS. (2015). Clozapine REMS: The single shared system for clozapine<\/em>. https:\/\/www.clozapinerems.com\/CpmgClozapineUI\/rems\/pdf\/resources\/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdf<\/a><\/u><\/p>\n Funk, M. C., Beach, S. R., Bostwick, J. R., Celano, C. M., Hasnain, M., Pandurangi, A., Khandai, A., Taylor, A., Levenson, J. L., Riba, M., & Kovacs, R. J. (2018). Resource document on QTc prolongation and psychotropic medications<\/em>. American Psychiatric Association. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Directories\/Library-and-Archive\/resource_documents\/Resource-Document-2018-QTc-Prolongation-and-Psychotropic-Med.pdf<\/a><\/u><\/p>\n Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13<\/em>(2), 261\u2013276.\u00a0https:\/\/doi.org\/10.1093\/schbul\/13.2.261<\/a><\/u><\/p>\n Levenson, J. C., Kay, D. B., & Buysse, D. J. (2015). The pathophysiology of insomnia. Chest, 147<\/em>(4), 1179\u20131192. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4388122\/<\/a><\/u><\/p>\n McClellan, J. & Stock. S. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 52<\/em>(9), 976\u2013990. https:\/\/www.jaacap.org\/article\/S0890-8567(09)62600-9\/pdf<\/a><\/u><\/p>\n Naber, D., & Lambert, M. (2009). The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians. CNS Drugs, 23<\/em>(8), 649\u2013659. https:\/\/doi.org\/10.2165\/00023210-200923080-00002<\/a><\/u><\/p>\n <\/p>\n Medication Resources (click to expand\/reduce) <\/a><\/u><\/strong><\/p>\n <\/p>\n U.S. Food & Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs<\/em>. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm<\/a><\/u><\/p>\n <\/p>\n Note:\u00a0<\/strong>To access the following medications, use the Drugs@FDA resource. Type the name of each medication in the keyword search bar. Select the hyperlink related to the medication name you searched. Review the supplements provided and select the package label resource file associated with the medication you searched. If a label is not available, you may need to conduct a general search outside of this resource provided. Be sure to review the label information for each medication as this information will be helpful for your review in preparation for your Assignments.<\/p>\nNURS 6630 Therapy for Patients With Schizophrenia Reference:
\n<\/sub><\/h2>\n![\"NURS](\"https:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2021\/10\/NURS-6630-Therapy-for-Patients-With-Schizophrenia-300x128.png\")
Learning Objectives<\/strong><\/h2>\n
Students will:<\/strong><\/h3>\n
\n
Learning Resources<\/strong><\/h2>\n
Click here to ORDER an A++ paper from our MASTERS and DOCTORATE WRITERS: NURS 6630 Therapy for Patients With Schizophrenia<\/strong><\/a><\/span><\/h3>\n